Live
- APSSDC signs tripartite MoU to upgrade skills of AP youth
- ‘AAP govt settling Rohingyas in Delhi, giving voter cards’
- Students advised to pursue excellence through learning
- Cold wave hits AP, Telangana: temperatures plunge to single digits
- AAP replaces Gahlot with another Jat face in Cabinet
- A Rising Star in Indian Cinema
- Telangana Introduces EV Policy to Prevent Severe Air Pollution
- Group- III exams conclude
- Ghose probe panel to summon KCR, Harish
- AP assembly meeting begins with question hour, several bills to be introduced
Migraine injection developed by Dr Reddy's now available in US market
Dr Reddy\'s Laboratories (DRL) in an announcement stated that their acute migraine treatment injection ZembraceSymTouch is now commercially available in the US market.
New Delhi : Dr Reddy's Laboratories (DRL) in an announcement stated that their acute migraine treatment injection ZembraceSymTouch is now commercially available in the US market.
In a BSE filling, the company said that 'Promius Pharma LLC', a subsidiary of DRL announced that ZembraceSymTouch injection is now commercially available in the US.
They received an approval from the US Food and Drug Administration (USFDA) for ZembraceSymTouch injection in January this year. ZembraceSymTouch is available as a prefilled, ready to use, single dose disposable injector.
At the time of USFDA approval, DRL had said the new product will be marketed in the US by Promius Pharma.
"ZembraceSymTouch is the first branded product in the company's neurology portfolio," DRL Executive Vice President Propriety Products Group, Raghav Chari said.
